Mammalian target of rapamycin (mTOR) kinase is a protein that regulates cell growth, proliferation and metabolism. mTOR Kinase Inhibitor II WYE-354 (also known as WYE354) is a small molecule inhibitor of mTOR kinase that has shown promising results in preclinical trials for the treatment of various types of cancer.
Chemical name: N-(4-((2-(aminopyrimidin-4-yl)amino)-4-chlorophenyl)-3-(trifluoromethyl)phenyl)acetamide Molecular formula: C19H15ClF3N5O Formula weight: 435.8 g/mol CAS No: 1062169-56-5
Top ten keywords and synonyms from Google search:
Health benefits of this product include its ability to inhibit the activity of mTOR kinase, which plays a critical role in regulating cell growth, proliferation and metabolism. By blocking mTOR kinase, WYE-354 can potentially slow down or stop tumor growth in various types of cancer.
Potential effects of WYE-354 include inhibition of tumor growth, induction of apoptosis in cancer cells, and modulation of immune response in various types of cancer. Preclinical studies have shown that WYE-354 can enhance the effectiveness of other anticancer agents when used in combination therapy.
The mechanism of action for WYE-354 involves inhibition of mTOR kinase, a protein that regulates cell growth, proliferation and metabolism. By blocking mTOR kinase, WYE-354 can potentially slow down or stop tumor growth in various types of cancer.
Safety is an important consideration when using any therapeutic agent. Preclinical studies have shown that WYE-354 has a favorable safety profile, with no evidence of significant toxicity or adverse effects at therapeutic doses. However, as with any drug, careful monitoring and dose adjustment may be needed to minimize the risk of side effects.
Common side effects associated with WYE-354 include fatigue, nausea, diarrhea, and rash. These side effects are generally mild and self-limiting, and most patients tolerate treatment well.
Dosing information for WYE-354 varies depending on the patient's age, weight, and medical history. It is typically administered orally once daily, and the recommended dose range is 1-50 mg/day.
In conclusion, mTOR Kinase Inhibitor II WYE-354 is a promising small molecule inhibitor of mTOR kinase that has shown potential as a molecular targeted therapy for various types of cancer. Its ability to regulate cell growth and metabolism makes it a potentially powerful tool for treating diseases characterized by uncontrolled cell growth. While it has a favorable safety profile, careful monitoring and dose adjustment may be necessary to minimize the risk of side effects. Further clinical studies are needed to determine the full therapeutic potential of this compound
